Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Clinical trial allocation in multinational pharmaceutical companies - a qualitative study on influential factors

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Pharmacokinetic variability of beta-adrenergic blocking agents used in cardiology

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Polypharmacy and medication deprescribing: A survey among multimorbid older adults in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Inconsistencies in dosage practice in children with overweight or obesity: A retrospective cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Mechanical and vasomotor properties of piglet isolated middle cerebral artery

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Biased small-molecule ligands for selective inhibition of HIV-1 cell entry via CCR5

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Total burden of disease in cancer patients at diagnosis-a Danish nationwide study of multimorbidity and redeemed medication

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Clinical trial allocation in multinational pharmaceutical companies includes country selection and site selection. With emphasis on site selection, the overall aim of this study was to examine which factors pharmaceutical companies value most when allocating clinical trials. The specific aims were (1) to identify key decision makers during country and site selection, respectively, (2) to evaluate by which parameters subsidiaries are primarily assessed by headquarters with regard to conducting clinical trials, and (3) to evaluate which site-related qualities companies value most when selecting trial sites. Eleven semistructured interviews were conducted among employees engaged in trial allocation at 11 pharmaceutical companies. The interviews were analyzed by deductive content analysis, which included coding of data to a categorization matrix containing categories of site-related qualities. The results suggest that headquarters and regional departments are key decision makers during country selection, whereas subsidiaries decide on site selection. Study participants argued that headquarters primarily value timely patient recruitment and quality of data when assessing subsidiaries. The site-related qualities most commonly emphasized during interviews were study population availability, timely patient recruitment, resources at the site, and site personnel's interest and commitment. Costs of running the trials were described as less important. Site personnel experience in conducting trials was described as valuable but not imperative. In conclusion, multinational pharmaceutical companies consider recruitment-related factors as crucial when allocating clinical trials. Quality of data and site personnel's interest and commitment are also essential, whereas costs seem less important. While valued, site personnel experience in conducting clinical trials is not imperative.

Original languageEnglish
JournalPharmacology Research & Perspectives
Volume5
Issue number3
Pages (from-to)e00317
ISSN2052-1707
DOIs
Publication statusPublished - Jun 2017

    Research areas

  • Journal Article

ID: 51775919